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Highlights 
 Crude extracts of the plant Fagonia cretica stimulate GLP-1 and GIP secretion 
 Ethyl acetate partitioning significantly enriches GLP-1 secretory activity 
 Quinovic acid (QA) & 2 QA derivatives are potent & selective GLP-1 secretagogues 
 QA and its derivatives stimulate GLP-1 secretion by activation of TGR5 receptors 
 
 
Abstract 
Selective GLP-1 secretagogues represent a novel potential therapy for type 2 diabetes mellitus. 
This study examined the GLP-1 secretory activity of the ethnomedicinal plant, Fagonia cretica, 
which is postulated to possess anti-diabetic activity. After extraction and fractionation extracts 
and purified compounds were tested for GLP-1 and GIP secretory activity in STC-1 pGIP/neo 
cells. Intracellular levels of incretin hormones and their gene expression were also determined. 
Crude F. cretica extracts stimulated both GLP-1 and GIP secretion, increased cellular hormone 
content, and upregulated gene expression of proglucagon, GIP and prohormone convertase. 
However, ethyl acetate partitioning significantly enriched GLP-1 secretory activity and this 
fraction underwent bioactivity-guided fractionation. Three isolated compounds were potent 
and selective GLP-1 secretagogues:  quinovic acid (QA) and two QA derivatives, QA-3β-O-β-
D-glycopyranoside and QA-3β-O-β-D-glucopyranosyl-(281)--D-glucopyranosyl ester. All 
QA compounds activated the TGR5 receptor and increased intracellular incretin levels and 
gene expression. QA derivatives were more potent GLP-1 secretagogues than QA. This is the 
first time that QA and its naturally-occurring derivatives have been shown to activate TGR5 
and stimulate GLP-1 secretion. These data provide a plausible mechanism for the 
ethnomedicinal use of F. cretica and may assist in the ongoing development of selective GLP-
1 agonists.  
 
 
Key words: GLP-1, GIP, incretin, secretagogue, TGR5. 
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1. Introduction 
Pharmacological interventions targeting the enteroinsular axis are a clinically-proven approach 
for improving glucose homeostasis in patients with type 2 diabetes mellitus [20]. Clinically 
approved pharmacological strategies include mimetics and analogues of glucagon-like peptide-
1 (GLP-1), but also inhibitors of dipeptidylpeptidase-4 (DPP-4i or gliptins) which act to 
prevent the physiological breakdown of GLP-1 and its sister hormone glucose-dependent 
insulinotropic polypeptide (GIP) [7, 11-12, 20]. A third, more unestablished strategy is the 
enhancement of postprandial GLP-1 secretion by means of specific secretagogues [25]. The 
functioning of the enteroinsular axis is markedly affected by the onset of type 2 diabetes. On 
one hand there is clear evidence of impaired GIP action but not GIP secretion [15, 23, 34-35].  
On the other hand defective or blunted GLP-1 secretion has been reported in type 2 diabetes 
on some occasions [23, 33-35]. Despite these observations of impaired GLP-1 secretion in type 
2 diabetes GLP-1-based therapies retain an ability to stimulate insulin secretion from pancreatic 
beta-cells [15]. One future alternative to GLP-1 analogue/mimetic therapy could involve ways 
of selectively increasing endogenous GLP-1 secretion. This approach could potentially even 
be used in combination with gliptin therapies in order to further enhance levels of active 
endogenous GLP-1. 
 
There is evidence that enhancement of endogenous postprandial GLP-1 secretion is an effective 
strategy. For example, dosing with the GLP-1 secretagogue L-Arginine increases circulating 
GLP-1 levels in both lean and obese mice, and it substantially improves glucose clearance [5]. 
GLP-1 receptor signalling appears to be pivotal since improvements in glucose tolerance are 
significantly less effective in GLP-1R-/- mice than wild-type littermates [5]. A number of other 
dietary-based GLP-1 secretagogues have been reported [4, 13, 17, 22, 26] but 
pharmacologically there is a focus on targeting several intestinal GPCRs believed to be 
important in modulating gut hormone secretion. These include the bile acid receptor TGR5 
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[25] and fat-sensing receptors GPR40, GPR119, and GPR120 [38] all of which are present on 
the surface of enteroendocrine cells.  
 
The present study investigated the incretin hormone secretory activity of the plant Fagonia 
cretica which was identified by routine systematic screening of plant materials. Although there 
is negligible scientific evidence that F. cretica possesses anti-diabetic activity [29] it is 
noteworthy that it is reportedly used in natural folk/Greco-Arab medicine for the treatment of 
diabetes [1, 3, 9]. Medicinal plants have been used to treat diabetes for millennia, and they 
offer a natural resource of anti-diabetic products for traditional ethnomedical systems in Asia 
and Africa. The prevalence of type 2 diabetes is rising fastest among developing countries [16] 
where 75-80% of the population relies on traditional herbal medicines for their primary 
healthcare [18]. Hence, there is a pressing need for the scientific characterisation of the 
numerous anti-diabetic medicinal plants described in traditional ethnomedical systems 
worldwide.  There are a number of examples of commonly used clinical anti-diabetic therapies 
which are based on natural products. For example, the most commonly used anti-diabetic drug 
metformin is based on the discovery of galegine in the plant Galega officinalis [2]. 
Furthermore, the widely used anti-diabetic drug acarbose (an alpha glucosidase inhibitor) was 
discovered in a bacterium [32]. The present study sought to identify novel ethnobotanical 
compounds which preferentially stimulate GLP-1 secretion but not GIP secretion. 
 
 
2. Materials and Methods 
2.1 Plant material 
An ongoing programme of work involving systematic screening of plant materials for incretin 
secretory activity led us to focus on Fagonia cretica (Synonym F. indica). The fresh aerial 
parts of plants were collected in Pakistan in September 2010. F. cretica (locally referred to as 
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Dhamasa) was collected from Mianwali. Plant species identification was carried out by 
Professor Dr. Rizwana Aleem Qureshi, Department of Plant Sciences, Faculty of Biological 
Sciences, Quaid-i-Azam University, Islamabad, Pakistan. Voucher specimens (HMP-461) 
were deposited in the “Herbarium of Medicinal Plants of Pakistan”, Quaid-i-Azam University, 
Islamabad, Pakistan. 
 
2.2 Extraction and isolation of F. cretica compounds  
The fresh aerial parts of F. cretica were rinsed with water, dried and crushed to dry weight to 
yield 22 kg of plant material. Crude plant extract (FCC) was prepared by maceration in a 
methanol-chloroform (1:1) solution for 7 days at room temperature. Extracts were filtered, 
concentrated with a rotary evaporator (45˚C) under vacuum and the resulting crude was 
suspended in water. The water suspension was partitioned three times with n-hexane to obtain 
an n-hexane fraction (FCN). The residual aqueous suspension was then partitioned with ethyl 
acetate to obtain an ethyl acetate (FCE) fraction and an aqueous fraction (FCA). Each of the 
above fractions were concentrated in a rotary evaporator. A total of 3 compounds with GLP-1 
secretory activity were isolated from FCE. All 3 compounds were obtained by chromatographic 
separation on a silica gel column, and their isolation and identification has previously been 
described in detail [29]. Compounds were identified by a combination of mass spectrometry 
and NMR spectroscopy (Bruker AVANCE 400 MHz NMR). Chemical structures were 
confirmed by comparison of their chemical and spectroscopic properties (as previously 
reported [29]). The compounds were: quinovic acid (QA), quinovic acid-3β-O-β-D-
glycopyranoside (dQA), and quinovic acid-3β-O-β-D-glucopyranosyl-(281)--D-
glucopyranosyl ester (EdQA). Structures of QA, dQA and EdQA can be found in the 
Supplementary Appendix (Figure 1). 
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2.3 Cells  
pGIP/Neo STC-1 cells were a gift from Dr. B. Wice (Washington University of St. Louis) [28] 
with permission from Dr D. Hanahan (University of California, San Francisco, CA). These 
cells secrete both GLP-1 and GIP and are responsive to nutrient stimulation and are potentially 
a very useful model for studying the secretory responses of both incretin hormones [10, 14, 
26]. DMEM culture medium containing 4.5 g/l with L-glutamine, without sodium pyruvate 
(Life Technologies, Paisley, UK) and supplemented with 10% foetal bovine serum, 100 U/ml 
penicillin, 100 mg/l streptomycin and geneticin - G418, 400 μg/ml purchased from Sigma 
(Dorset, UK).  pGIP/Neo STC-1 cells were cultured in culture medium and incubated in a 5% 
CO2 humidified atmosphere at 37C. Cells underwent passage upon reaching 80–90% 
confluence and were used for studies between passage numbers 15–50. 
 
2.4 GLP-1 and GIP Secretion 
Cells were seeded into 12-well plates (2 x 106 per well) and cultured overnight at 37 °C in a 
humidified atmosphere of 5% CO2.  Medium was removed and cells washed 3 times with 
HEPES buffer (20 mM HEPES, 10 mM glucose, 140 nM NaCl, 4.5 mM KCl, 1.2 mM CaCl2, 
1.2 mM MgCl2) then allowed to incubate for 1h in HEPES buffer prior to adding fresh HEPES 
buffer (vehicle control) or HEPES buffer supplemented with test agents.  Cells were incubated 
for 3 h after which the vehicle control and test agents were removed, centrifuged and stored at 
-80C prior to ELISA assays. GLP-1 and GIP ELISA kits were purchased from Millipore 
(Billerica, MA, USA).  GLP-1 assays detected only active forms of GLP-1 (7-36 amide and 7-
37) whilst GIP assays detected total GIP (GIP (1-42) and GIP (3-42).   
 
2.5 Cellular GLP-1 and GIP content 
Cellular GLP-1 and GIP peptide levels were determined in pGIPneoSTC-1 cells after 
incubations with plant extract/compounds. Initially cells (2 x 106) were seeded into 12 well 
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plates and cultured overnight at 37°C in a humidified atmosphere of 5% CO2. Medium was 
removed and replaced with 1 ml of medium supplemented with 50 µM of the plant 
extract/compound. Following incubation the medium was removed and cells were washed with 
1ml of HEPES buffer and GLP-1and GIP were extracted by the addition of acid/ethanol (1.5% 
HCl (v/v): 75% ethanol (v/v): 23.5% H2O (v/v)) and incubated overnight at 4°C. Acid/ethanol 
solutions were removed, centrifuged (2000 g, 5 min) to remove cellular debris, and the ethanol 
evaporated off using a SpeedVac sample concentrator (Genevac, Ipswich, UK). Samples were 
reconstituted in buffer and stored at -80°C prior to measurement by ELISA. 
        
2.6 Real-time PCR  
Cells (4 x 106 per well) were seeded into 6-well culture plates with 1 ml of culture medium, 
allowed to attach overnight (24h; 37°C; 5%CO2). Medium was removed, the cells were washed 
with HEPES buffer and then underwent pre-incubation with HEPES buffer (60 min). Buffer 
was aspirated off and cells were incubated for 3h with 400μl of plant extracts (250 µg/ml) and 
isolated compounds (50 µM). The vehicle control was unsupplemented HEPES buffer. After 
the test period samples were removed and the cells were trypsinised, centrifuged to obtain a 
pellet. RNA was isolated from pellet by using RNeasy Mini Kit (Qiagen). The purity of isolated 
RNA was determined using UV absorption at 260 and 280 nm. The cDNA was synthesized 
from 2μg of total RNA using dNTP, random primers and reverse transcriptase (High capacity 
cDNA reverse transcription kits, Applied Biosystems). Real-time PCR was performed using 
SYBR green PCR master mix and a SYBR green Real-time PCR reagents kit (Applied 
Biosystems). Sequences of custom synthesis primers (Invitrogen) used to amplify the cDNAs 
of interest can be found in the Supplementary Appendix (Table 1). All reactions were 
performed in Eco™ Real-Time PCR System with Eco™ software v3.1.7.0 (Illumina) and 
underwent PCR (95ºC for 10 min; then 40 cycles of denaturation at 95ºC for 30 sec, annealing 
at 61ºC for 30 sec, and extension at 72 ºC 30 sec). 
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2.7 Measurement of cytotoxicity and cell numbers 
Cells were seeded into 96-well plates (5 x 104 per well) and cultured overnight at 37 °C in a 
humidified atmosphere of 5% CO2.  Cells were exposed to test agents for 3 h after which 
medium and test agents were removed from the wells, Alamar blue (Invitrogen, NY, USA) 
added (100µl), the plate incubated (37C; 1h) and absorbance read (570 - 600 nm) using a 
microplate reader (Tecan, Safire2).   Parallel incubations were set up for measurement of cell 
numbers but after media was removed cells were fixed with 10% formalin for 10 min at room 
temperature.  Cells were washed (x4) with PBS and permeabilization solution (0.25% Triton 
X-100 in PBS) added and incubated for 30 min at room temperature.  Cells were washed with 
PBS (3 times x 5 min) in the dark after which Hoechst staining solution was added for 10 min. 
Cells were washed with PBS (x1) and PBS added to each well and the plate was sealed prior 
to fluorescent imaging 350-461 nm with an ArrayScan high content analysis system (Thermo, 
Loughborough, UK). 
 
2.8 Measurement of TGR5 receptor activation 
Stimulation of cAMP response was measured in CHO cells stably expressing human TGR5 
(GPBAR1) via cAMP Hunter™ eXpress assay kit (DiscoveRx Corporation, Birmingham, UK). 
In brief, cells re-suspended (10,000 in 10 μl/well) in Hank’s balanced salt solution (137 mM 
NaCl, 5.4 mM KCl, 0.25 mM Na2HPO4, 0.44 mM KH2PO4, 1.3 mM CaCl2, and 1.0 mM 
MgSO4) with 25 mM HEPES and 0.01% (w/v) BSA were stimulated in the presence of plant 
extracts and compounds (5 μl/well) in a 96-well plate at room temperature for 30 min before 
adding antibody and lysis reagents according to manufacturer’s protocol. The plates were 
further incubated in the dark overnight after adding detection solution, and read using a Mithras 
LB940 Luminometer (Berthold Technologies, Germany) for 1 min per plate. Data were 
expressed as Relative Luminescence Unit (RLU) and forskolin (5 μM; 5 μl/well) was used as 
a positive control.  
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2.9 Statistical analysis 
Experimental data were expressed as mean ± SEM and analyzed by one-way ANOVA with 
Tukey’s post-hoc test (GraphPad Prism version 5). P values less than 0.05 were deemed 
statistically significant.  
 
 
3. Results 
3.1  F. cretica plant extracts stimulate incretin hormone secretion and gene expression. 
F. cretica extracts (125-250µg/ml) significantly stimulated GLP-1secretion (3-55-fold; 
P<0.05; Figure 1A-B). GIP secretion was also significantly stimulated by F. cretica plant 
extracts although the effect was more modest (1.6-2.2-fold; P<0.05 Figure 1C-D). Gene 
expression of proglucagon (2.2-6.4-fold; P<0.001 Figure 2A), GIP (6.2-12.3-fold; P<0.001; 
Figure 2B) and PC1/3 (1.8-2.4-fold; P<0.001; Figure 2C) were all increased by exposure of 
cells to F. cretica extracts, and cell viability was largely unaffected (Figure 2D) except for 
FCA. Solvent partitioning of FCC with ethyl acetate (FCE) enriched GLP-1 secretory activity 
(41-55-fold) and proglucagon gene expression (6.4-fold) to the greatest extent. Contrastingly, 
no parallel improvement in GIP secretion was observed with FCE compared with FCC. For 
this reason FCE underwent further bioactivity-guided chromatographic separation.  
 
3.2 Isolated F. cretica compounds stimulate GLP-1 secretion, upregulate incretin-related gene 
expression and increase cellular hormone content. 
The 3 isolated compounds QA, dQA and EdQA were all capable of significantly stimulating 
GLP-1 secretion (Figure 3A-B), without triggering GIP secretion (Figure 3C-D). The most 
potent secretagogue appeared to be EdQA.  EdQA was the only compound to significantly 
increase GLP-1 secretion at 25µM (Figure 3A; 1.6-fold; P<0.05), and at a concentration of 50 
µM it gave a much GLP-1 secretory response (Figure 3B; 16.9-fold; P<0.001) than either QA 
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or dQA (5.8 and 8.7-fold, respectively; P<0.001). QA modestly upregulated the expression of 
the proglucagon gene (Figure 4A; 50µM; 2.4-fold; P<0.01) but did not affect the expression of 
GIP or prohormone convertase (PC1/3) genes (Figure 4B-C). Contrastingly, dQA and EdQA 
increased the expression of proglucagon (4.6 and 7.9-fold, respectively; p<0.001), GIP (1.9 
and 2.2-fold, respectively; p<0.001) and PC1/3 genes (1.8 and 3.4-fold, respectively; p<0.001).  
In all cases EdQA increased gene expression by the greatest extent. None of the compounds 
had adverse effects on cell viability, but in the case of EdQA a slight improvement was noted 
(Figure 4D; 1.1-fold; P<0.05) along with a significant increase in both the GLP-1 and GIP 
cellular content (Figure 4F-G; 1.3 and 2.1-fold, respectively; P<0.01).  Cell numbers were 
unaffected by any treatments (Figure 4E). 
 
3.3 Isolated F. cretica compounds activate the TGR5 receptor 
All 3 isolated compounds were capable of significantly increasing cAMP production in a TGR5 
overexpressing cell-line (Figure 5). At a concentration of 100 µM QA, dQA and EdQA 
increased cAMP production by 1.6, 1.6 and 1.5-fold, respectively (P<0.001). EdQA was the 
only compound to significantly increase cAMP production at 33µM (1.2-fold; P<0.05).  
 
 
4. Discussion 
This investigation isolated and identified three novel GLP-1 secretagogue compounds 
occurring in a plant reportedly used in traditional ethnomedical systems to treat diabetes. Our 
focus on F. cretica was prompted by the results of screening studies which found that crude 
extracts potently stimulated incretin hormone secretion.  A crude F. cretica extract potently 
stimulated the secretion of both GLP-1 and GIP, and increased the cellular levels of these 
hormones. The extract also increased the expression of proglucagon, GIP and PC1/3 genes. 
The aim of the study was to identify compounds which preferentially stimulate GLP-1 
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secretion. Therefore, bioactivity-guided fractionation was performed on the fraction yielded by 
ethyl acetate partitioning due to the observed enrichment in activity. In fact partitioning with 
ethyl acetate increased GLP-1 secretory activity more than 2-fold, and quite remarkably the 
overall GLP-1 concentrations after exposure were 41-55-fold higher compared with the vehicle 
control. In contrast, similar partitioning of the extract did not improve GIP secretion. The 3 
compounds isolated and identified QA, dQA and EdQA all potently stimulated GLP-1 
secretion, but importantly not GIP secretion. Their ability to activate the TGR5 receptor was 
subsequently confirmed by measurement of intracellular cAMP production in CHO cells 
transfected with TGR5 (Figure 5).  As far as we are aware QA has not previously been reported 
to possess either GLP-1 secretory activity or TGR5 agonism. There are a variety of G protein-
coupled receptors (GPCR) which play a role in modulating GLP-1 secretion, but TGR5 
(GPBAR1) appeared to be the most logical target for these QA-derived compounds for several 
reasons. Firstly, the compounds appeared to stimulate cAMP in STC-1 pGIP neo cells (data 
not shown). GLP-1 secretion both in vitro and in vivo has been linked to Gs-coupled GPCRs 
which increase cAMP and activate PKA [30]. TGR5 is one such GPCR which was first 
discovered in 2002 and apparently acts physiologically as the primary mediator of bile-acid 
induced GLP-1 release [19, 21]. Pharmacologically-designed TGR5 agonist molecules are 
potent GLP-1 secretagogues and they appear to enhance L-cell responses to Ca2+ and glucose-
induced GLP-1 secretion [24]. Secondly, STC-1 cells (of which STC-1 pGIP neo cells are a 
sub-clone) express significant amounts of TGR5 and the application of a TGR5 agonist to STC-
1 cells increases the gene expression of PC1/3 [37] which was also upregulated in the present 
study. Thirdly, and perhaps most importantly QA is a triterpenoid compound and other 
naturally-occurring triterpenoid compounds have been shown to activate TGR5. For example, 
oleanolic acid is a triterpenoid extracted from Olea europaea leaves which stimulates GLP-1 
secretion and possesses an antihyperglycaemic effect [27, 31). Finally, it is worth mentioning 
that dQA and EdQA isolated here, are QA compounds derivatised at the C-3 and C-17 carbon 
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positions. Since dQA and EdQA (especially EdQA) possessed greater GLP-1 secretory activity 
than QA, derivatisation at these positions can be generally viewed as beneficial. Such an 
observation appears to be analogous to the structure-activity relationship studies of [8] who 
found that the TGR5 receptor activity of betulinic acid (another natural triterpenoid) could be 
improved by modification at the same carbon positions where dQA and EdQA are derivatised. 
In this regard QA could be viewed as an alternative chemical scaffold for the discovery and 
development of novel pharmacological TGR5 agonists – a class of compounds which is 
undergoing pre-clinical development as potential orally-deliverable therapies for type 2 
diabetes [6, 25]. In addition to stimulating GLP-1 secretion TGR5 agonists offer other potential 
benefits for type 2 diabetic patients. Most notably they increase energy expenditure by 
increasing oxidative phosphorylation in the mitochondria of brown fat cells and skeletal muscle 
cells [22, 36]. It has been postulated that TGR5 therefore could have additional benefits in type 
2 diabetes mellitus because patients have disproportionately higher levels of obesity [25]. 
 
Before optimal dosages for F.cretica can be determined quantitative analytical measurement 
of the QA compounds in F.cretica should to be conducted. However, based on the data obtained 
during the original fractionation of F.cretica, approximately 13mg of these QA compounds 
were isolated from 100g of an ethyl acetate extract (FCE) [29]. In vivo dose ranging studies 
should be conducted for F.cretica with measurement of plasma GLP-1 and plasma glucose as 
endpoints. 
 
 
5. Conclusion 
In conclusion, we have discovered three naturally occurring TGR5 agonists which potently 
stimulate GLP-1 secretion. The compounds provide a novel and plausible mechanism 
supporting the ethnomedicinal use of F. cretica in traditional ethnomedical systems. 
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Furthermore, the results indicate that QA could be used a potential chemical scaffold for the 
discovery and development of pharmacological TGR5 agonists, which are currently under 
investigation for the treatment of type 2 diabetes mellitus [25]. Structure-activity related studies 
of QA are clearly warranted. Finally, there is a need for in vivo studies in diabetic animal 
models to scientifically validate the potential glucose-lowering effects of F. cretica. This is 
especially interesting given that compounds in F. cretica including QA derivatives have modest 
inhibitory activity against DPP-4 [29] which may contribute to GLP-1 duration of action.  
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Figure Legends 
 
Figure 1. Effects of F. cretica plant extracts on GLP-1 and GIP secretion. STC-1 pGIPneo 
cells were incubated for 3h before determination of (A-B) GLP-1 secretion and (C-D) 
GIP secretion. Crude plant extract (FCC) was prepared by maceration in methanol-
chloroform (1:1) and other extracts were prepared by partitioning with n-hexane (FCN), 
ethyl acetate (FCE) and aqueous (FCA) solvent phases. Results are mean ± SEM (n=3). 
*P<0.05, **P<0.01 and ***P<0.001.  
 
Figure 2. F. cretica plant extracts influence incretin hormone biosynthesis. FCC, FCN, 
FCE and FCA affected expression of (A) proglucagon (GLP-1), (B) GIP and (C) PC1/3 
genes. (D) Only FCA significantly affected cell viability. Cellular content of (E) GLP-
1 and (F) GIP were also affected by plant extracts. Results are mean ± SEM (n=3). 
*P<0.05, **P<0.01 and ***P<0.001 compared with control, ns- not significant. 
 
Figure 3.  Compounds isolated from F. cretica stimulate secretion of GLP-1 but not GIP. 
QA, dQA and EdQA were isolated and identified from FCE. At a concentration of 
50µM QA, dQA and EdQA all stimulated GLP-1 secretion (5.1-16.9-fold). EdQA also 
significantly increased GLP-1 secretion at 25µM. No comparable secretory effect for 
GIP was observed. Results are mean ± SEM (n=3). *P<0.05, **P<0.01 and ***P<0.001 
compared with control, ns- not significant. 
 
Figure 4. Compounds isolated from F. cretica influence incretin hormone biosynthesis. 
QA, dQA and EdQA affected the expression of (A) proglucagon (GLP-1), (B) GIP and 
(C) PC1/3 genes in STC-1 pGIP neo cells. Only EdQA significantly improved cell 
viability (D) whilst cell numbers (E) were unaffected by treatments. Improvements in 
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the cellular content were noted for GLP-1 (F) and GIP (G). Results are mean ± SEM 
(n=3). **P<0.01 and ***P<0.001 compared with control, ns- not significant. 
 
Figure 5. Compounds isolated from F. cretica activate the TGR5 receptor. TGR5 receptor 
activation was determined by measurement of cAMP production in CHO cells stably 
expressing human TGR5 (GPBAR1). CHO QA, dQA and EdQA all activated TGR5 at 
a concentration of 100µM. EdQA also appeared to activate TGR5 at 33µM. Results are 
mean ± SEM (n=3). *P<0.05 and ***P<0.001 compared with control, ns- not 
significant. 
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